Evotec SE ADR EVO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Evotec Secures $2.9 Million Grant to Advance Early Drug Safety Testing Using Human Stem Cell Technology
Evotec Reports Third Quarter and Nine-Month 2026 Results: Building Growth Momentum Toward 2030 Goals
Evotec SE to Announce Results for the First Nine Months 2026 on November 5, 2026
Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board
Evotec Announces Chief Scientific Officer Transition
Just - Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical Studies
Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors
Trading Information
- Previous Close Price
- $1.56
- Day Range
- $1.44–1.49
- 52-Week Range
- $1.33–3.87
- Bid/Ask
- $1.25 / $1.80
- Shares Outstanding
- 355.39M
- Market Cap
- $525.98M
- Volume/Avg
- 63,613 / 106,222
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.63
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 0.32%
Company Profile
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 4,553
- Website
- https://www.evotec.com
Valuation
Metric | EVO |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.73 |
Price/Sales | 0.63 |
Price/Cash Flow | — |
Price/Earnings
EVO
Financial Strength
Metric | EVO |
|---|---|
Quick Ratio | 2.06 |
Current Ratio | 2.32 |
Interest Coverage | −11.76 |
Quick Ratio
EVO
Profitability
Metric | EVO |
|---|---|
Return on Assets (Normalized) | −9.86% |
Return on Equity (Normalized) | −22.34% |
Return on Invested Capital (Normalized) | −13.63% |
Return on Assets
EVO
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|!B@M<#> | LOCK|Bb#R? | $72B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|cXHR%^X | LOCK|&$$% | $49B | |||
| Haleon PLC ADR HLN | LOCK|ZHvgCMH | LOCK|#^^ | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|wFM<dm# | LOCK|>p# | $34B | |||
| Viatris Inc VTRS | LOCK|&cySZ%$ | LOCK|%?R | $23B | |||
| Elanco Animal Health Inc ELAN | LOCK|m% | LOCK|?Yt | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|xz>^KQ | LOCK|LH | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|W&mc&V& | LOCK|GW | $4B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|>CBtVw | LOCK|>N?T# | $2B | |||
| Perrigo Co PLC PRGO | LOCK|v%Z>SQ | LOCK|kw< | $2B |